Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen boosted by EPO hearing

Shares of Transkaryotic Therapies (TKTX) closed Wednesday at $53, down $25.125 (32 percent) on the week, after a U.S. District Court judge adopted modified versions of Amgen's definitions of four patent claim terms related to AGMN's erythropoietin patent infringement suit against TKTX and partner Aventis Pharmaceuticals.

Judge William

Read the full 483 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers